MISSISSAUGA, ON, Aug. 21, 2014 /CNW/ - Eisai Limited is pleased to support the Canadian Epilepsy Alliance (CEA) in the introduction of the first-of-its-kind comic book available in Canada. The comic book, an innovative educational tool, has been designed specifically to educate children and their parents about epilepsy, the most common neurological disorder in Canada affecting more than 300,000 Canadians. Eisai is guided by a corporate philosophy known as human health care (hhc), in which the patient is central – there was a need within the epilepsy community to help facilitate greater understanding of the disorder for future generations and this certainly aligns with hhc.
"The CEA is always looking for innovative ways to educate Canadians about epilepsy," says Oliver Technow, President and General Manager, Eisai Limited. "Their latest initiative, the MediKidz comic book, takes a unique approach to educating children in a format that resonates, we also know that this will help to inform teachers and parents who may not be familiar with the most common neurological condition in Canada."
Authored by doctors and medical writers, the book's content addresses the mechanics, diagnosis, and treatment of epilepsy and is peer-reviewed by leading medical professionals and endorsed by the Canadian epilepsy community. The MediKidz Explain Epilepsy will be made available through the Canadian Epilepsy Alliance across the country.
About Eisai Limited
Eisai established the Canadian pharmaceutical company Eisai Limited in 2010. As a wholly-owned subsidiary of Eisai Inc., Eisai Limited is based in Mississauga, Ontario, one of the largest biopharmaceutical clusters and medical communities in North America. For more information about Eisai in Canada, please visit www.eisai.ca
About Eisai Inc.
At Eisai Inc., human health care is our goal. We give our first thoughts to patients and their families. As the U.S. pharmaceutical subsidiary of Tokyo-based Eisai Co., Ltd., our passionate commitment to patient care is the driving force. We are a fully integrated pharmaceutical business with discovery, clinical, manufacturing and marketing capabilities. To learn more about Eisai Inc., please visit us at www.eisai.com/US.
Eisai Inc. has affiliates that are part of a global product creation organization that includes R&D facilities in Massachusetts, New Jersey, North Carolina and Pennsylvania, as well as a global demand chain organization that includes manufacturing facilities in Maryland and North Carolina. Eisai's global areas of R&D focus include neuroscience; oncology; metabolic disorders; vascular, inflammatory and immunological reaction; and antibody-based programs.
SOURCE: Eisai Limited
For further information: Media Inquiries: Karen Law, Eisai Limited, 905-361-7136